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ABSTRACT
Background and study aims Endoscopic ultrasound-
guided gastroenterostomy (EUS-GE) with a lumen-appos-
ing metal stent (LAMS) is a novel, minimally invasive tech-
nique in the palliative treatment of malignant gastric outlet
obstruction (GOO). Several studies have demonstrated fea-
sibility and safety of EUS-GE, but evidence on long-term
durability is limited. The aim of this study was to evaluate
patency of EUS-GE in treatment of malignant GOO.
Patients and Methods An international multicenter study
was performed in seven centers in four European countries.
Patients who underwent EUS-GE with a LAMS between
March 2015 and March 2019 for palliative treatment of
symptomatic malignant GOO were included retrospective-
ly. Our main outcome was recurrent obstruction due to
LAMS dysfunction; other outcomes of interest were techni-
cal success, clinical success, adverse events (AEs), and sur-
vival.
Results A total of 45 patients (mean age 69.9 ±12.3 years
and 48.9% male) were included. Median duration of follow-
up was 59 days (interquartile range [IQR] 41–128). Recur-
rent obstruction occurred in two patients (6.1%), after 33
and 283 days of follow-up. Technical success was achieved
in 39 patients (86.7%). Clinical success was achieved in 33
patients (73.3%). AEs occurred in 12 patients (26.7%), of
which five were fatal. Median overall survival was 57 days
(IQR 32–114).
Conclusions EUS-GE showed a low rate of recurrent ob-
struction. The relatively high number of fatal AEs under-
scores the importance of careful implementation of EUS-
GE in clinical practice.
Original article
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Introduction
Malignant gastric outlet obstruction (GOO) can occur in up to
20% of patients with advanced or metastatic malignancies lo-
cated in the distal stomach and peri-pancreatic region [1]. Ac-
companying obstructive symptoms such as vomiting and nau-
sea are a burden to patients and quickly lead to malnutrition
and poor performance status [2]. Given its advanced and often
metastatic or unresectable stage, the main purpose of treating
malignant GOO is palliation of these obstructive symptoms.
Traditionally, the two techniques to treat malignant GOO are
endoscopic duodenal stent placement and surgical gastrojeju-
nostomy (SGJ). Both interventions are effective palliative treat-
ments with high success rates. Duodenal stent placement is
minimally invasive and associated with favorable short-term re-
sults, such as fast relief of symptoms and improvement in food
intake. However, a significant risk of late adverse events (AEs)
was found, such as stent migration and recurrent obstruction,
often necessitating reintervention [3–7]. SGJ provides longer-
lasting patency with less need for reinterventions once the
anastomosis is functioning and patients have recovered [3, 8–
10], but it is a more invasive treatment and associated with sur-
gery-related morbidity such as gastroparesis or intestinal pa-
ralysis [11].
Endoscopic ultrasound-guided gastroenterostomy (EUS-GE)
with a lumen-apposing metal stent (LAMS) is a novel technique
for palliative treatment of malignant GOO. It seems to combine
the advantages of duodenal stenting and SGJ, while potentially
overcoming their shortcomings [12–16]. EUS-GE is minimally
invasive and shows fast relief of symptoms, possibly with lower
stent failure and reintervention rates than duodenal stenting
[12, 13]. It also avoids invasive surgery and related morbidity
of SGJ, but might provide comparable long-term patency [14,
15].
Long-term patency of EUS-GE is crucial for maintaining oral
intake and quality of life. However, current literature on dur-
ability of EUS-GE is limited. We aimed to assess recurrent ob-
struction and patency of EUS-GE in a multinational cohort of
patients with malignant GOO.
Patients and methods
Patients with symptomatic malignant GOO who underwent
EUS-GE with a LAMS were retrospectively included. Twenty-six
European centers with known expertise in interventional
endoscopy and LAMS were invited to participate in this study
(▶Fig. 1). In total, seven centers (six tertiary centers, one large
regional center) from four countries (four centers from the
Netherlands and one from Germany, Spain, and Italy) provided
consecutive cases, from the first EUS-GE procedures performed
in each hospital. Procedures were performed between March
2015 and March 2019. A subset of 10 patients has been report-
ed previously [17]. Baseline characteristics (age, sex, obstruc-
tive symptoms, and diet tolerated before and after EUS-GE,
etiology of malignant GOO, location of the obstruction, per-
formance status, presence of ascites or peritoneal carcinoma-
tosis, previous oncologic treatment); procedural characteristics
(year of intervention, method of stent placement, size of stent,
balloon dilation of the stent, antibiotic administration), and fol-
low-up data after EUS-GE (recurrent obstruction, technical and
clinical success, time to oral intake, diet tolerated after techni-
cally successful EUS-GE, AEs, death, cause of death, duration of
follow-up and survival) were retrospectively collected from
electronic medical records. Data were stored in Castor EDC, a
General Data Protection Regulation (GDPR) compliant Electro-
nic Data Capture Tool.
Patients were eligible if they presented with symptomatic
malignant GOO (nausea, vomiting, and intolerability of oral in-
take) due to obstruction confirmed endoscopically and/or by
abdominal imaging, and had undergone EUS-GE with LAMS
(Hot AXIOS Stent).
Additional information was requested from participating
centers, general practitioners or treating physicians if data
were missing or interpretation was hampered. Uncertainties
about eligibility and outcome adjudication were discussed in a
panel of two expert endoscopists from UMC Utrecht for con-
sensus. For quality assurance, we excluded a series of 17 pa-
tients from one center, because in more than 50% of these pa-
tients eligibility could not be verified or follow-up was lacking.
This study was approved by the Institutional Medical Research
Ethics Committee of the University Medical Center Utrecht
(MREC number 18/584) and complied with the GDPR at each
participating institution. This study adhered to the Strengthen-
ing the Reporting of Observational Studies in Epidemiology
(STROBE) Guidelines [18].
EUS-GE procedural techniques
EUS-GE procedures and per procedural care were performed ac-
cording to local practice and endoscopists’ preference. Either
the direct puncture technique or the balloon-assisted technique
was performed [19]. A gastroscope was introduced proximal to
the stenosis and a feeding tube was placed distal to the stenosis
through the working channel. The endoscope was then re-
Invited European centres with LAMS expertise 
(n=26)
Initially agreed to participate (n = 12)
Declined invitation (n = 14)
▪ No response (n = 7)
▪ Not performing EUS-GE (n = 6)
▪ Participation in another
 project (n = 1)
Centres included (n = 6)
Refrained from participation (n = 6)
▪ No further response (n = 2)
▪ Not possible to provide data (n = 4)
▶ Fig. 1 Centers included in the study.
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moved, followed by introduction of a linear array EUS endo-
scope. With the direct puncture technique, the jejunal or duo-
denal loop was identified by flushing saline with indigo carmine
through the feeding tube into the post-stenotic duodenal-jeju-
nal loop.With the balloon-assisted method, an extraction bal-
loon was used for identification of the duodenal-jejunal loop.
Identification of the loop could be confirmed with puncture
and aspiration of luminal content with a 25G “finder needle.”
Subsequently, the loop was punctured using an electrocautery-
enhanced delivery system and the 15×10mm or 20×10mm
LAMS (Hot AXIOS Stent and Electrocautery-Enhanced Delivery
System, Boston Scientific Corporation, United States) was de-
ployed. Correct positioning and passage of the stent was con-
firmed fluoroscopically and endoscopically by backflow of the
indigo-colored saline from the small intestine into the stomach.
Subsequent balloon dilation of the LAMS was performed at the
discretion of the endoscopist.
Outcomes and definitions
The main outcome was recurrent obstruction. It was defined as
recurrence of GOO symptoms (nausea, vomiting, inability to
tolerate oral intake) after a clinically successful EUS-GE, con-
firmed by endoscopy or abdominal imaging showing a dysfunc-
tional LAMS.
Other outcomes of interest were as follows. Technical suc-
cess was defined as adequate positioning and deployment of
the LAMS, confirmed by endoscopy or fluoroscopy. Successful
stent-in-stent placement of a second LAMS or a FCSEMS after
the initial attempt failed was also considered technically suc-
cessful. Clinical success was defined as the ability to tolerate at
least a full liquid diet without vomiting, after a technically suc-
cessful EUS-GE. The ability of oral food intake was measured by
the Gastric Outlet Obstruction Scoring System (GOOSS) score
as adapted by Adler et al: 0 = no oral intake, 1 = liquid intake
only, 2 = soft solids, 3 = low residue/full diet [2]. AEs were de-
fined as any AE occurring during EUS-GE or within the first
month of follow-up suspected to be related to EUS-GE. Severity
was graded according to the ASGE lexicon [20]. Survival was de-
fined as the time between EUS-GE and death.
Follow-up
Patients were followed up until death or last contact as report-
ed in the electronic patient files. Additional information about
events during follow-up was requested from general practition-
ers or treating physicians if follow-up was missing or unclear.
We considered patients free of recurrent obstruction if no re-
current obstructive symptoms were recorded at last contact
(physical or by telephone) or before death.
Statistical analysis
Baseline characteristics are presented as means and standard
deviations (SD) for normally distributed continuous variables
and medians with interquartile range (IQR) for continuous vari-
ables with a skewed distribution. Absolute numbers and per-
centages are presented for categorical variables. Patients were
censored at their last moment of contact if they were lost to fol-
low-up. Due to the limited sample size, no subgroup analyses
were performed. Statistical analyses were performed with
STATA version 15.1 and R version 3.5.1 was used for plotting
the bar chart.
Results
Baseline characteristics
In total, 45 patients (48.9% male; mean age 69.9 ±12.3 years)
who underwent EUS-GE with a LAMS for symptomatic malig-
nant GOO were included in this study. Twenty-one patients
(46.7%) presented with inability to tolerate oral intake
(GOOSS 0) and 21 (46.7%) tolerated liquids only (GOOSS 1).
Nausea was reported in 27 patients (62.8%) and vomiting in
38 (88.4%). Etiologies of malignancies causing GOO are shown
in ▶Table 1. Fifteen patients (35.7%) had ascites and 13
(33.3%) had peritoneal carcinomatosis. Nine (23.7%) had both
ascites and peritoneal carcinomatosis. Seventeen patients
(38.6%) had not undergone oncological treatment, 16 (36.4%)
were previously treated with chemotherapy, 15 (34.1%) receiv-
ed a duodenal stent, and four (9.1%) had surgery within this
anatomical region. These operations included a Whipple in
two patients, pylorus-preserving pancreaticoduodenectomy in
one and Roux-en-Y reconstruction in one (▶Table 1).
Procedural characteristics
The direct technique was used in 36 patients (80.0%) and the
balloon-assisted technique was applied in nine (20.0%). The
diameter of the deployed LAMS was 15mm in 32 patients
(72.7%) and 20mm in 12 patients (27.3%). Balloon dilation im-
mediately after stent placement was performed in 12 proce-
dures (30.8%). Pre-procedural antibiotics were administered
to 18 patients (40.0%) and post-procedural antibiotics were ad-
ministered to 28 patients (62.2%) (▶Table 2).
Outcomes
Recurrent obstruction
Two of 33 patients (6.1%) had recurrent obstruction after a
clinically successful EUS-GE, occurring after 33 and 283 days
(▶Table3). Median duration of follow-up in patients with clini-
cal success was 73 days (interquartile range [IQR] 44–166). In
both patients, repeat endoscopy was performed and showed a
LAMS with a small luminal diameter and food impaction. The
LAMS could not be passed with the endoscope. This was suc-
cessfully solved endoscopically by removal of the food and bal-
loon dilation. There were no signs of tissue in- or overgrowth.
One additional patient underwent repeat endoscopy for recur-
rent obstructive symptoms after initial clinical success, but the
LAMS was functional in this patient.
Technical and clinical success
Technical success was accomplished in 39 patients (86.7%)
(▶Table3). The six technical failures were related to stent mis-
placement in five patients, and to accidental puncture of a co-
lonic loop with the finder needle and abortion of the procedure
in one patient. Stent misplacement occurred initially in eight
patients, but could be salvaged with a second LAMS (stent-in-
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stent) in two patients and a FCSEMS (stent-in-stent) in one pa-
tient, resulting in a technically successful EUS-GE. Of the five
patients in whom stent misplacement could not be salvaged,
one patient underwent immediate surgical removal of the stent
with closure of the perforation and four patients were managed
endoscopically in the same session (duodenal stent placement
in one patient; conservative treatment after removal of stent
and closure with clip in three patients). Technical success was
achieved in 10 of 13 patients (76.9%) with peritoneal carcino-
matosis and in 24 of 26 (92.3%) without peritoneal carcinoma-
tosis. Eleven of 15 patients (73.3%) with ascites and 25 of 27
(92.6%) without ascites were technically successful. Technical
success was achieved in six of nine patients (66.7%) with both
peritoneal carcinomatosis and ascites.
Clinical success was achieved in 33 patients (73.3%) who un-
derwent EUS-GE (84.6% of the patients who underwent a tech-
nically successful EUS-GE). Fifteen patients (38.5%) were able
to tolerate soft solids (GOOSS 2) and 18 (46.2%) low residue/
full diet (GOOSS 3). Median time to resumption of oral intake
was 1 day, ranging from 0 to 4 days. Of the five patients in
whom EUS-GE was clinically unsuccessful, two died before hav-
ing the opportunity to resume oral intake and three who ex-
perienced persistent obstructive complaints were treated with
PEG feeding and/or anti-emetics. One of these patients pres-
ented at a later stage with a metastatic transverse colon ob-
struction for which a colon stent was placed. Clinical success
was achieved in eight of 10 patients (80.0%) with peritoneal
carcinomatosis and in 22 of 24 patients (91.7%) without perito-
neal carcinomatosis. Ten of 11 (90.9%) patients with ascites
and 21 of 25 patients (84.0%) without ascites had clinical suc-
cess. Clinical success was achieved in six of six patients (100%)
with both peritoneal carcinomatosis and ascites.
Adverse events
AEs occurred in 12 patients (26.7%), of which five after stent
misplacement. In two patients (4.4%) AEs were mild, consisting
of seeking post-procedural medical consultation for abdominal
pain. In one patient this was after accidental puncture of a co-
lonic loop and an aborted procedure; the other returned to the
Emergency Room 3 days after a successful EUS-GE. No abnorm-
alities were diagnosed, and both were successfully treated with
analgesics and antibiotics. In four patients (8.9%) AEs were
moderate, requiring prolonged hospitalization of 4 to 10 days
to administer antibiotics. Antibiotics were administered as pro-
phylaxis after stent misplacement (n =1), due to an E. coli bac-
▶Table 1 Baseline characteristics.
Age, mean ± SD 69.9 ± 12.3
Male sex, n (%) 22 (48.9)
GOOSS score before EUS-GE
▪ GOOSS 0 (no oral intake), n (%) 21 (46.7)
▪ GOOSS 1 (liquid only), n (%) 21 (46.7)
▪ GOOSS 2 (soft solids), n (%)  3 (6.7)
▪ GOOSS 3 (low residue/full diet) –
Median GOOSS score before EUS-GE (IQR)  1 (0–1)
Obstructive symptoms, n (%)1
▪ Nausea 27 (62.8)
▪ Vomiting 38 (88.4)
▪ Early satiety 15 (34.9)
▪ Anorexia 18 (41.9)
▪ Epigastric pain 17 (39.5)
▪ Weight loss 23 (53.5)
Aetiology, n (%)
▪ Pancreatic cancer 19 (42.2)
▪ Extrinsic/metastatic cancer2  8 (17.8)
▪ Gastric cancer  6 (13.3)
▪ Duodenal cancer  3 (6.7)
▪ Periampullary cancer  3 (6.7)
▪ Biliary tract cancer  3 (6.7)
▪ Gall bladder cancer  2 (4.4)
▪ Lymphoma  1 (2.2)
Location of obstruction, n (%)3
▪ Antrum/pylorus 10 (22.7)
▪ 1st/superior part duodenum (bulb) 14 (31.8)
▪ 2nd/descending part duodenum 17 (38.6)
▪ 3rd/horizontal part duodenum  7 (15.9)
Ascites, n (%) 15 (35.7)
Peritoneal carcinomatosis, n (%) 13 (33.3)
WHO performance status, n (%)
▪ 0 –
▪ 1 11 (25.6)
▪ 2 22 (51.2)
▪ 3 10 (23.3)
▪ 4 –
Previous oncologic treatment, n (%)4
▪ None 17 (38.6)
▪ Chemotherapy 16 (36.4)
▪ Duodenal stent 15 (34.1)
▪ Surgery5  4 (9.1)
1 Multiple symptoms per patient possible.
2 Primary disease included colon carcinoma (n=3), urinary bladder cancer
(n=3), pNET(n =1), hepatobiliary adenocarcinoma of unknown origin
(n=1).
3 More than one obstructed duodenal part per patient possible.
4 More than one oncologic treatment per patient possible.
5 Surgery included a Whipple (n =2), pylorus-preserving pancreaticoduode-
nectomy(n=1) and Roux-en-Y reconstruction (n =1).
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teraemia (n =1), infection without focus (n =1), and local ab-
dominal pain with elevated inflammatory markers (n =1). The
latter three occurred after technically and clinically successful
EUS-GE. All patients recovered well. One patient (2.2%) under-
went emergency surgery 13 days after the initial EUS-GE, be-
cause of stent dislocation during repeat endoscopy with jejuno-
scopy through the LAMS. This was considered a severe AE. Five
AEs (11.1%) were fatal, four of which were due to stent mispla-
cement with perforation and abdominal sepsis and one was due
to a post-procedural intraperitoneal haemorrhage, noted 24
hours after a technically successful procedure (▶Table 4).
Survival
During median overall follow-up of 59 days (IQR 41–128), 32
patients (71.1%) died. Causes of death are shown in ▶Table 3.
Median overall survival (OS) was 57 days (IQR 32–114). Median
survival of patients after technically successful EUS-GE was 62
days (IQR 41–124), and 34 days (IQR 2–57) after technical fail-
ure. Thirteen patients were alive at last contact. Survival is illu-
strated in ▶Fig. 2.
Discussion
This study describes the first European multicenter cohort of
patients with malignant GOO who underwent EUS-GE. Recur-
rent obstruction occurred in two patients (6.1%) after clinical
success, as a result of a narrowed luminal diameter of the
LAMS and food impaction. Technical and clinical success was
achieved in 86.7% and 73.3%, respectively. AEs occurred in 12
patients (26.7%). Median OS was 57 days.
EUS-GE with LAMS is a novel technique to treat malignant
GOO. It has the theoretical advantage of a lower risk of dysfunc-
tion due to stent migration and tumour ingrowth, because of
features such as the biflanged, short length, and fully-covered
design, and its positioning outside the tumoral area [16, 21,
22]. In the literature, several studies showed low rates of recur-
rent obstruction after EUS-GE. These rates varied between 0%
and 4.8%, when defined as recurrent GOO symptoms due to
LAMS dysfunction in clinically successful patients [12–14, 16,
19, 21, 23, 24]. Causes of stent dysfunction included food im-
paction, inflammatory tissue overgrowth, and stent ingrowth
[12–14, 19,23]. A buried gastric flange of a LAMS has also
been reported recently [25].
▶Table 2 Procedural characteristics.
Year of EUS-GE, n (%)
▪ 2015 10 (22.2)
▪ 2016  5 (11.1)
▪ 2017  7 (15.6)
▪ 2018 20 (44.4)
▪ 2019  3 (6.7)
Method of stent placement, n (%)
▪ Direct technique 36 (80.0)
▪ Balloon-assisted  9 (20.0)
Diameter stent, n (%)
▪ 15mm 32 (72.7)
▪ 20mm 12 (27.3)
Balloon dilation, n (%) 12 (30.8)
Pre-procedural antibiotics, n (%) 18 (40.0)
▪ β-lactam 14 (77.8)
▪ Other1  4 (22.2)
Post-procedural antibiotics, n (%) 28 (62.2)
▪ β-lactam 22 (78.6)
▪ Other2  6 (21.4)
EUS-GE, endoscopic ultrasound-guided gastroenterostomy
1 Other antibiotics prior to EUS-GE: β-lactam+metronidazole (n =2), vanco-
mycin (n=1), ciprofloxacin (n =1).
2 Other antibiotics after EUS-GE: β-lactam+metronidazole (n=4), vancomy-
cin (n=1), ciprofloxacin (n =1).
▶Table 3 Outcomes after EUS-GE.
Recurrent obstruction, n (%)  2 (6.1)
Technical success, n (%) 39 (86.7)
Clinical success, n (%) 33 (73.3)
Diet tolerated after technically successful EUS-GE
▪ GOOSS 0  5 (12.8)
▪ GOOSS 1 1 (2.6)1
▪ GOOSS 2 15 (38.5)
▪ GOOSS 3 18 (46.2)
Adverse events, n (%) 12 (26.7)
Death, n (%) 32 (71.1)
Cause of death, n (%)
▪ Progressive disease 19 (59.4)
▪ Stent-related  5 (15.6)
▪ Other cause  4 (12.5)2
▪ Unknown  4 (12.5)
Median survival after EUS-GE in days (IQR) 57 (32–114)
▪ Median survival after technical successful EUS-GE
(IQR)
62 (41–124)
▪ Median survival after technical failed EUS-GE (IQR) 34 (2–57)
Median follow-up in days (IQR) 59 (41–128)
EUS-GE, endoscopic ultrasound-guided gastroenterostomy; IQR, interquar-
tile range
1 This patient had persistent complaints of occasional vomiting and was not
considered clinically successful.
2 Other causes of death include chemotherapy complications, euthanasia,
nosocomial pneumonia, kidney failure.
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In comparative studies where EUS-GE was compared with
duodenal stenting, significantly lower rates of GOO symptom
recurrence after EUS-GE were found [12, 13]. In Ge et al, stent
failure requiring repeat intervention occurred in two (8.3%)
LAMS versus 31 (32.0%) duodenal stent placements (P=
0.021); calculated per stent placed [13]. In Chen et al, GOO re-
currence after clinical success occurred in one (4.0%) EUS-GE
patient versus 10 (28.6%) duodenal stent patients (P=0.015)
[12]. When comparing the same 30 EUS-GE patients with 63
SGJ patients, long-term patency was not significantly different,
with one patient (3%) experiencing recurrent GOO symptoms
after EUS-GE versus nine patients (14%) after SGJ (P=0.08)
[14]. Though the number of patients in these studies was small,
data were collected retrospectively and treatment was not allo-
cated randomly, it is suggested that EUS-GE could provide an
effective and durable alternative for duodenal stenting and SGJ
[12–14].
The technical success rate in our study was 86.7%. In pre-
vious reports, technical success rates ranged from 86.7% to
100% [12–16, 19, 23]. Inclusion of multiple interventional
endoscopists could have influenced our rate of technical suc-
cess, since each endoscopist reported their first EUS-GE cases
performed. Five technical failures were due to distal flange mis-
placement. Four of these cases occurred in a centre in which
the first cases were performed with the over-the-guidewire
technique, before the free hand technique was applied. The for-
mer technique was abandoned later, because it was noted that
pushing the guidewire could cause the jejunum to move away
from the stomach, resulting in maldeployment of the LAMS
[24]. In the fifth case, presence of ascites between the stomach
and the jejunum was deemed to preclude technical success.
Our clinical success rate of 73.3% is lower than previously re-
ported rates of 83.3% to 95.8% [12–16, 19, 23]. Inclusion of be-
nign causes of GOO in some of the previous studies may have
contributed to higher rates of clinical success, because most of
the clinically unsuccessful patients in our study were suspected
of having a distal intestinal obstruction or an intestinal motility
disorder due to advanced malignancy hindering clinical success
[15, 16, 19, 23]. In addition, the number of patients with fatal
AEs was higher in our study and these patients did not have
the chance to regain their ability to eat and become clinically
successful.
Our total number of 12 patients with AEs (26.7%)was higher
compared with previously reported rates ranging from 3.5% to
▶Table 4 Grading of severity of adverse events after EUS-GE.
Grading of adverse events N patients
(%)
Mild:
▪ Seeking medical consultation for abdominal pain  2 (4.4)
Moderate:
▪ Antibiotics administration with 4–10 nights pro-
longed hospitalization
 4 (8.9)
Severe:
▪ Emergency surgery for stent dislocation  1 (2.2)
Fatal:
▪ Perforation leading to abdominal sepsis, n = 4
▪ Post-procedural intraperitoneal haemorrhage, n =1
 5 (11.1)
Total 12 (26.7)
EUS-GE, endoscopic ultrasound-guided gastroenterostomy
1
N = 10
N = 13
N = 5
N = 2 N = 2 N = 2
N = 3
N = 1 N = 1 N = 1N = 1
N = 0 N = 0 N = 0 N = 0
N = 4
2 3 4 5 6 7 8
Follow-up (months)
Alive at last contact
Died after technical failed EUS-GE
Died after technical successful EUS-GE    
Survival after EUS-GE
9 10 11 12 13 14 15 16
Su
rv
iv
al
 (%
)
30
20
10
0
▶ Fig. 2 Survival after EUS-GE.
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20.8% [12–16, 19, 23]. This difference could be explained by
the difficulty of retrospective registration of AEs, when avail-
able data can be sparse and inconsistent. We found six (13.3%)
mild or moderate AEs that were related to inflammation, anti-
biotic administration or pain after EUS-GE, which is deemed
acceptable after a procedure such as EUS-GE. The stent disloca-
tion during jejunoscopy through the LAMS in one patient, 13
days after the initial EUS-GE, underscores the importance of al-
lowing a mature anastomosis to be formed before it can safely
be passed with an endoscope. The number of five fatal AEs in
our study, in particular, was higher than in previous reports. Al-
though the percentage of stent misplacements (17.8%) in our
study was in line with the previously reported percentages be-
tween 7% and 36% [12–16, 19, 24], it resulted in perforation
with fatal peritonitis and abdominal sepsis in 4 of our patients.
The fifth patient died from intraperitoneal bleeding after a
technically successful procedure. Fatal peritonitis after perfora-
tion is a previously reported AE after EUS-GE [15, 16]. Post-pro-
cedural bleeding was also reported previously, but occurred
after failed stent placement and was managed successfully
with blood transfusions [15, 16].
The number of fatal AEs in our study may not reflect con-
temporary practice but rather individual learning curves and
development of technical and clinical practice over recent
years. All fatal AEs and most stent misplacements occurred in
one center, early after the introduction of EUS-GE. EUS-GE
technique has been refined over time (e. g. elimination of
guidewire assistance, development of a technique to salvage
initial failed placements) and more knowledge about the risks
and pitfalls of performing EUS-GE became available [26]. More-
over, interventional endoscopists who began performing EUS-
GE more recently may have more experience with LAMS, as it
is more routinely used for other indications. It highlights,
nevertheless, the challenging character and potential risks of
EUS-GE, even for experienced interventional endoscopists.
Stent misplacement can be fatal, especially in vulnerable and
debilitated patients, and pursuing successful stent placements
through sufficient training and expertise is crucial.
Our median OS and follow-up were 57 and 59 days, respec-
tively. Recently, Kerdsirichairat et al reported 48 patients with
malignant GOO, with a median follow-up of 196 days (IQR
50.5–278.5), the longest follow-up to date [23]. In our study,
the duration of follow-up was shorter, partly due to lost contact
after referral back to other hospitals or outpatient palliative
care, but most importantly due to short survival of our patients.
The rate of recurrent obstruction due to LAMS dysfunction was
nevertheless low in patients who were followed until death.
We performed an international multicenter study including
seven centers from four European countries. All centers used
the same type of LAMS (Hot AXIOS stent). We included conse-
cutive cases from the first EUS-GE procedures performed in
each centre, to limit selection bias. Treating physicians and
general practitioners were contacted to complete follow-up as
much as possible and to minimize bias due to missing data.
This study has several limitations. Patients were retrospec-
tively identified, and data were retrospectively collected and
interpreted from patient records. Participating centres could
have used different selection criteria for EUS-GE, as uniform
criteria are currently not available. Patients presenting with ma-
lignant GOO who underwent SGJ or duodenal stenting during
the study period were not collected and could not be used as
comparison group.Our median OS prevents drawing conclu-
sions about long-term patency of LAMS.Due to the palliative
care setting, standardized follow-up endoscopies were not per-
formed. Repeat endoscopies were only performed in case of re-
current obstructive symptoms. Therefore, we do not have infor-
mation on the quality of the LAMS in patients who did not re-
port recurrent obstructive symptoms. Recent reports showed
that the coating of the LAMS was degraded in some cases and
luminal narrowing of the LAMS has occurred due to hyperplas-
tic tissue ingrowth [13, 27, 28]. LAMS mesh erosion has also
been reported [13]. Whether these features could also have oc-
curred in patients who did not report recurrent obstructive
symptoms, or were potentially masked by the debilitating
course of progressive disease, is unknown. The effect of learn-
ing curve on outcomes could not be assessed due to the small
number of patients treated by each endoscopist. Although a
lower technical success rate was observed in patients with
both peritoneal carcinomatosis and ascites, the amount of as-
cites and peritoneal carcinomatosis and its association with
outcomes could not be quantified retrospectively. The size of
our cohort did not allow adjustment for patient and procedural
characteristics. All but one participating centre were large ter-
tiary centers, possibly hampering generalizability to other cen-
ters.
Prospective and comparative studies, ideally with random-
ized treatment allocation, low rate of attrition, and sufficient
duration of follow-up, are warranted to determine the role of
EUS-GE in relation to SGJ and duodenal stenting. At this mo-
ment, EUS-GE can be considered in patients with a reasonable
life expectancy, such as those who typically qualify for SGJ.
Duodenal stent placement, which carries less risk, remains the
preferred treatment in patients with a short life expectancy.
Conclusion
In conclusion, this international, multicenter, observational co-
hort study of EUS-GE as treatment of malignant GOO showed
low recurrent obstruction rates due to LAMS dysfunction. It
suggests that EUS-GE has the potential to be a durable and
minimally invasive alternative treatment option, although the
limited OS in this cohort does not allow for conclusions to be
drawn about long-term outcomes. In addition, EUS-GE remains
a challenging technique that requires expertise in LAMS place-
ment and careful implementation in clinical practice, as stent
misplacement can lead to serious AEs.
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